further develop biomarker-guided therapies in clinical trials.14Significant methodological advances in biomarker-guided clinical trial designs have been made toward patient-centered trials, including the basket, umbrella, and platform trial designs under the master protocol framework.15,16A master protocol r...
National Cancer Institute’s Malignant Mesothelioma Resources http://www.cancer.gov/cancertopics/types/malignantmesothelioma National Cancer Institute provides extensive mesothelioma resources about malignant mesothelioma, its treatment, causes, clinical trials, and other pertinent information. OncoLink http://...
Emerging treatments for mesothelioma can be modified versions of existing ones or entirely new therapies altogether. New mesothelioma treatments are currently being studied in clinical trials across the country. Examples of emerging mesothelioma treatments include: Immunotherapy Gene therapy Vaccine therapy Stu...
Mesothelioma cancer historically has affected men. But now women comprise nearly one-fourth of all cases and incidence rates among women are on the rise.
New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials. Cancer Manag Res. 2015;7:51‐63.Kotova S, Wong RM, Cameron RB. New and emerging therapeutic options for malignant pleural mesothelioma: review of early clinical trials. Cancer Manage...
Other cancers may also be targeted with this new approach, e.g., hard-to-treat cancers such as mesothelioma and pancreatic cancer. In order to attack large tumors with adoptive cellular therapy, it seems pivotal that the T cells proliferate to achieve an appropriate effector-to-target cell rat...
It has been shown that ASS1 is not expressed in a number of different malignancies including some melanoma, prostate cancer, hepatocellular carcinoma, mesothelioma and bladder cancers.3,4,5 Given that this loss of ASS1 expression, and therefore the ability to synthesise arginine de novo is ...
Kaira K, Oriuchi N, Takahashi T, Nakagawa K, Ohde Y, Okumura T, Murakami H, Shukuya T, Kenmotsu H, Naito T, Kanai Y, Endo M, Kondo H, Nakajima T, Yamamoto N: L-type amino acid transporter 1 (LAT1) expression in malignant pleural mesothelioma. Anticancer Res. 2011, 31: 4075-...
Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc. Natl. Acad. Sci. USA 1996, 93, 136–140. [Google Scholar] [CrossRef] [Green Version] Hassan, R.; Thomas, A.; Alewine, C.; Le, D.T.; Jaffee, E.M.; Pastan...
criteria. A slight bias was detected in the comparison of basic clinical characteristics between the two groups. RFA showed a significant advantage in the length of hospital stay (median; 2 days vs. 7 days;p< 0.001). The 1- and 3-year PFS in the liver resection and the RFA groups was...